Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Financing

Set Alert for Financing

Finance Watch: No New IPOs, But Two Firms Take The SPAC Route

Public Company Edition: NewAmsterdam grossed $328m in its SPAC merger, while Liminatus may raise up to $316m in a new SPAC deal. Also, Intellia and Iveric grossed $300m each in follow-on offerings, bluebird sold a PRV for $102m and MEI ends zandelisib development resulting in layoffs.

Financing Business Strategies

Pulmocide Grows Cash Pile For Promising Antifungal

The UK firm has announced an extension of its series C financing which means it has raised just shy of $150m in the last 18 months to fund clinical development, manufacturing scale-up and preparations for the potential commercialization of opelconazole.

Financing Respiratory

Pfizer Backs EU Manufacturing With €2.4bn Investment

Pfizer is betting big on its manufacturing plans in Europe, investing €1.2bn at respective sites in Ireland and Belgium to prepare for a number of launches it has lined up in the short term.

Manufacturing Business Strategies

Chinese Biotechs Raise $212m Through Major VC/PE Deals in November

Leading the group were Trinomab Biotech, which develops antibodies for infectious diseases, and cell and gene developers BRL Medicine and XellSmart.

China Financing

Korean Bioventure Financing Continues Downward Spiral In Q3

VC Investment in South Korea’s biopharma sector drops again as investors continue to shy away amid higher interest rates and reduced out-licensing deals.

South Korea Financing

Finance Watch: CG Oncology, MBX, Jnana Bring In VC Mega-Rounds

Private Company Edition: In the latest round of $100m-plus venture capital financings, CG Oncology, MBX Biosciences and Jnana Therapeutics raised $120m, $115m and $107m, respectively. Also, MVM Partners closed a $500m fund and former Sage CEO leads incubator ABio-X in Massachusetts.

Financing Deals

Lysogene Shifts Sanfilippo Focus To Subgroup Following Pivotal Trial Flop

The French firm’s late-stage trial of its gene therapy candidate for Sanfilippo syndrome missed several endpoints but promising data from a cohort of young infants could help pave a way forward - if it can get more cash.

Clinical Trials Gene Therapy

How To Turn Around A Struggling Biotech

Leaders from three companies that have managed to achieve successful turnarounds offered some advice and encouragement to biotechs weathering the current financial downturn at the recent Jefferies Healthcare conference in London.

Companies Innovation

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: a market snapshot of inflammatory bowel disease; will biotech bounce back in 2023?; Phase III miss for Roche’s Alzheimer’s candidate; how Japan’s top firms did in the quarter; and China showcase hints at policies and strategies.

Gastrointestinal Biologics

Govt-Led Innovation Support In Focus As Shanghai Biopharma Sector Rebounds

Shanghai’s biopharma sector has started to regain momentum and is beginning to see its innovation bets paying off, with support from the local government.

China Strategy

Finance Watch: Acrivon Adjusts Expectations To Launch $99.4m IPO

Public Company Edition: Acrivon launched the 20th biopharma IPO in the US for 2022. Also, Q3 updates reveal job cuts at Tricida, Harpoon, Neoleukin and more; APIM Therapeutics will reverse merge with Nordic Nanovector; plus other follow-on offerings, royalty deals and a sale-leaseback. 

Financing Business Strategies

After Cutting Back And Clinging On, Will Biotech Bounce Back In 2023?

Industry investors foresee continued hardship for public companies still without compelling clinical data for their assets, plus the growing influence of the US Inflation Reduction Act on biopharma strategy.

Companies Commercial
See All
UsernamePublicRestriction

Register